2021: The strategic opportunities for global medicines innovators in the UK
We firmly believe the UK’s post-Brexit regulatory picture provides a wealth of strategic opportunities for medicines innovators to advance clinical programmes here from both a Global and European perspective. As we embark on a new era the MHRA, as a world-class regulator, will establish an even stronger influence in regulatory guidance for clinical development and the UK should always be an early strategic consideration.
In our latest articles we cover:
- The UK post Brexit: the significant opportunities
- The MHRA post-Brexit: still delivering prompt, pragmatic and patient benefit-powered decisions that can be a strategic step in your clinical development